Cite
HARVARD Citation
Chau, I. et al. (n.d.). SO-002Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF). Annals of oncology. p. . [Online].